GlassScriptPhysician profile
Rose L Calixte
NPI 1750851861
$10,193.93
in general payments reported to CMS, 2019-2025
26 companies · $2,738 in 2025
The $2,738 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,597 · 2022: $1,680 · 2023: $2,090 · 2024: $2,090 · 2025: $2,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,837 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,836.67 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,769.63 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $1,600.20 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,110.95 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $820.96 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $725.29 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $693.69 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $560.62 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $503.71 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $369.61 | 2025 | Auvelity |
| Lundbeck LLC | $352.17 | 2021-2025 | Rexulti |
| Corium, LLC | $275.56 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $223.70 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $211.52 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $182.57 | 2021-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $176.25 | 2023-2024 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $123.88 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Adlon Therapeutics L.P. | $115.82 | 2021 | |
| Tris Pharma INC | $103.77 | 2023-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $73.08 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $63.33 | 2024 | |
| Eisai INC. | $34.91 | 2021 | |
| Currax Pharmaceuticals LLC | $25.18 | 2021 | |
| Noven Therapeutics, LLC | $22.60 | 2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $20.11 | 2025 | Jornay Pm |
| Livanova USA, INC. | $19.40 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Merck Sharp & Dohme LLC | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Calixte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.